Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Vanessa E. Kennedy, Cheryl A C Peretz, Andrew Koh, Elaine Tran, Dalia Dhingra, Saurabh Gulati, Adam Sciambi, Olga Sala-Torra, Lan Beppu, Aaron C. Logan, Alexander Perl, Wendy Stock, Geoffrey L Uy, Ann-Kathrin Eisfeld, Jerald P. Radich, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2023-182454

Published: 2023

Journal Articles

Mediator Kinase/CDK8 Inhibition As a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia

Timothy T. Ferng, Samantha M. Pintar, Vanessa E. Kennedy, Theodore C. Tarver, III, Shaheen Kabir, Veronica Steri, Juan Antonio Camara Serrano, Fernando Salangsang, Paul Phojanakong, Juwita Hübner, Carolina E. Morales, Jose M. Rivera, Aaron C. Logan, Benjamin Braun, Elliot Stieglitz, Luke A. Gilbert, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2023-180290

Published: 2023

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2023-181886

Published: 2023

Journal Articles

RAS MULTI (ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models

Bogdan Popescu, Elliot Stieglitz, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 2793.

https://doi.org/10.1182/blood-2023-178397

Published: 2023

Journal Articles

Threshold Attenuation of Perk Signaling Is Sufficient to Overcome RAS-Mediated FLT3 Inhibitor Resistance

Cheryl A C Peretz, Elaine Tran, Bogdan Popescu, Vanessa E. Kennedy, Tanya Kumar, Lisa McGary, Natalie Tantisira, Eric Wong, Jose M. Rivera, Simayijiang Xirenayi, Elliot Stieglitz, Catherine C. Smith, Juwita Hübner

Blood (2023) 142 (Supplement 1): 4171.

https://doi.org/10.1182/blood-2023-182426

Published: 2023

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

Single Cell Sequencing of Pediatric Acute Myeloid Leukemia Reveals Clonal Evolution to Relapse on Combination Chemotherapy with Sorafenib

Cheryl A C Peretz, Vanessa E Kennedy, Rhonda E. Ries, Soheil Meshinchi, Catherine C. Smith

Blood (2021) 138 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2021-150110

Published: 2021

Journal Articles

RNA Polymerase II Is a Therapeutic Target to Overcome FLT3 Inhibitor Resistance Mediated By the Bone Marrow Microenvironment

Timothy T. Ferng, Theodore C. Tarver, III, Shaheen Kabir, Benjamin Braun, Aaron C. Logan, Luke A. Gilbert, Catherine C. Smith

Blood (2021) 138 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2021-145835

Published: 2021

Journal Articles

Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia

Bogdan Popescu, Carlos Stahlhut, Theodore C. Tarver, III, Timothy T. Ferng, Cheryl Peretz, Sydney Wishner, Paul Phojanakong, Veronica Steri, Eric B. Wong, Jose M. Rivera, Elliot Stieglitz, Catherine C. Smith

Blood (2021) 138 (Supplement 1): 2231.

https://doi.org/10.1182/blood-2021-145964

Published: 2021

Journal Articles

Being Present-CML: A Distress Reduction Intervention for Patients with Chronic Myeloid Leukemia Taking Tyrosine Kinase Inhibitors

Kelly L. Schoenbeck, Anand Dhruva, Albert Lee, Neha G. Goyal, Adrienne K. Yang, Sa Ra Park, Catherine C. Smith, Neil P Shah, Chloe E. Atreya

Blood (2021) 138 (Supplement 1): 4051.

https://doi.org/10.1182/blood-2021-152076

Published: 2021

Journal Articles

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Kelly L. Schoenbeck, MD, Sirisha Tummala, MD, Rebecca L. Olin, MD, Neha G. Goyal, PhD, Anand Dhruva, MD, Lloyd E. Damon, MD, Aaron C. Logan, MDPhDMPhil, Catherine C. Smith, MD, Neil P. Shah, MDPhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-143303

Published: 2020

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-139705

Published: 2020

Journal Articles

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Alexander E. Perl, MD, Jessica K. Altman, MD, Naoko Hosono, MD PhD, Pau Montesinos, MD PhD, Nikolai A. Podoltsev, MD PhD, Giovanni Martinelli, MD, Catherine C. Smith, MD, Mark Levis, MD PhD, Christoph Röllig, Prof., MD, Marco Groß-Langenhoff, PhD, Nahla Hasabou, MD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-136395

Published: 2020

Journal Articles

Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic Phase

Kelly L. Schoenbeck, MD, Sirisha Tummala, MD, Neha G. Goyal, PhD, Catherine C. Smith, MD, Neil P. Shah, MDPhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142997

Published: 2020

Journal Articles

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, Alexander E. Perl, MD, Mark Levis, MD PhD, Catherine C. Smith, MD, Andrew M. Brunner, Koichi Takahashi, MD PhD, Philip C. Amrein, MD, Hanno R. Hock, MD PhD, Gabriela S. Hobbs, MD, Rupa Narayan, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Naval Daver, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-140118

Published: 2020

Journal Articles

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Varun Mittal, MD, Mimi Lo, PharmD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Thomas G. Martin, III, MD, Rebecca L. Olin, MD, Catherine C. Smith, MD, Aaron C. Logan, MD PhD

Blood (2019) 134 (Supplement_1): 5089.

https://doi.org/10.1182/blood-2019-129514

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

NARROW

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Mediator Kinase/CDK8 Inhibition As a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

RAS MULTI (ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models

Threshold Attenuation of Perk Signaling Is Sufficient to Overcome RAS-Mediated FLT3 Inhibitor Resistance

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Single Cell Sequencing of Pediatric Acute Myeloid Leukemia Reveals Clonal Evolution to Relapse on Combination Chemotherapy with Sorafenib

RNA Polymerase II Is a Therapeutic Target to Overcome FLT3 Inhibitor Resistance Mediated By the Bone Marrow Microenvironment

Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia

Being Present-CML: A Distress Reduction Intervention for Patients with Chronic Myeloid Leukemia Taking Tyrosine Kinase Inhibitors

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic Phase

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only